News and Trends 3 Mar 2023
Lilly to develop Confo pain drug
Confo Therapeutics, which works on the discovery of medicines targeting G-protein coupled receptors (GPCRs), has announced a worldwide licensing agreement…
GPCR
- Latest Posts
News and Trends 2 Mar 2023
Antiverse identifies therapeutic antibodies targeting GPCRs
Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding…
News and Trends 17 Feb 2023
Beyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics
Our Beyond Biotech podcast 34 guests are Katrina Rice, chief delivery officer, biometrics services at eClinical Solutions; Pina Cardarelli, president…
News and Trends 16 Feb 2023
Maxion Therapeutics raises $16M to target GPCRs
Biotechnology company Maxion Therapeutics has completed its $16 million Series A financing. The funds will be used to support the…
ADVERTISEMENT
News and Trends 2 Feb 2023
Orbit Discovery and Endevica Bio to develop cachexia therapeutics
Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for…
News and Trends 19 Jan 2023
GPCR Therapeutics launches multiple myeloma trial
GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial…
News and Trends 8 Dec 2022
Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders
Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University…
More News! 9 Nov 2022
PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way
PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized…
News and Trends 28 Apr 2022
OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B
The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules…
News and Trends 7 May 2019
Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets
Confo Therapeutics has raised €30M in a Series A round that will take its unique technology to find drugs for…
News and Trends 5 Oct 2017
British Biotech Founder Receives the Nobel Prize in Chemistry 2017
Richard Henderson, awarded the Nobel Prize in Chemistry 2017, founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines. This…
News and Trends 2 Oct 2017
Meet the Young CEO of a PCR Workflow Automation Company
He is a young entrepreneur with a fast growing company. His software for the automation of PCR results interpretation in…
News and Trends 26 Sep 2017
Belgian Biotech Teams Up With Lundbeck to Collaborate on Drug Discovery
Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo's special technology. Confo Therapeutics develops small…
News and Trends 1 Sep 2017
Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal
Allergan's partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer's disease.…
Interview 17 Jul 2017
Pinning Down Elusive Targets: Interviewing the Co-Founder & CSO of Heptares
Heptares is expanding into a range of indications with its GPCR platform. I caught up with CSO & co-founder Fiona…
News and Trends 19 May 2017
MorphoSys’ First Lanthipeptide Completes Phase I Successfully
UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed…
ADVERTISEMENT
News and Trends 18 May 2017
Heptares receives €4.5M Milestone for New Migraine Drug Candidate
The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches.…
News and Trends 27 Apr 2017
Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation
Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects.…
News and Trends 1 Feb 2017
Young Belgian Biotech will tackle Fibrosis with a New Grant
Confo Therapeutics has received a €1.6M grant to support the discovery of drugs against fibrosis, one of the most deadly…
News and Trends 31 Jan 2017
New British Biotech-Academia Alliance takes on Cardiovascular Disease
Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based…
